Zoledronic acid oral - Merrion

Drug Profile

Zoledronic acid oral - Merrion

Alternative Names: MER-101; Orazol

Latest Information Update: 10 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merrion Pharmaceuticals
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone metastases

Most Recent Events

  • 10 Sep 2015 No recent reports on development identified - Phase-II for Bone metastases in USA, Estonia and Latvia (PO)
  • 16 Nov 2010 Zoledronic acid oral is still in phase II trials in USA
  • 20 Oct 2009 Pharmacokinetics data from a clinical trial released by Merrion Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top